2024 January 11 release (#24)

vanallenlab · Jan 11, 2024 · 13609f2 · 13609f2
1 parent 4ee3078
commit 13609f2
Show file tree

Hide file tree

Showing 3 changed files with 58 additions and 25 deletions.
diff --git a/docs/content-changelog.md b/docs/content-changelog.md
@@ -1,6 +1,13 @@
 # Content Changelog
 The following changes have been made to the content catalogued within the Molecular Oncology Almanac knowledge base.
 
+## January 2024 release
+Added entries:
+- (FDA) _ERBB2_ amplification and sensitivity to neratinib in combination with capecitabine for patients with breast cancer.
+
+Revised entries:
+- (FDA) _ERBB2_ amplification and sensitivity to neratinib for patients with breast cancer, received an updated description and citation.
+
 ## December 2023 release
 Added entries:
 - (FDA) _PIK3CA_ and _AKT_ somatic variants and _PTEN_ loss of function variants and sensitivity to capivasertib in combination with fulvestrant for patients with breast cancer.

diff --git a/docs/sop.md b/docs/sop.md
@@ -99,7 +99,7 @@ The PDF should be saved as `{revised year}-{revised month}-{generic drug name}.p
 
 You can stay up to date on FDA approvals by visiting or subscribing to:
 - [FDA press announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements)
-- [FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications](https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications), a summary list of all approvals by year.
+- [FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications](https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications), a summary list of all approvals by date.
 - [FDA Oncology on Twitter (@FDAOncology)](https://twitter.com/FDAOncology)
 
 ###### Fields
@@ -137,14 +137,14 @@ Guidelines will complete fields as follows,
 - `last_updated`, with the last updated time
 - `doi`, `pmid`, and `nct` will be left blank
 
-The description for guidelines should brief readers on the assertion(s) made in the publication. For example, 
-> Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs.
+The description for guidelines should brief readers on the relationship, following the [NCCN's referencing guidance](https://www.nccn.org/docs/default-source/business-policy/nccn-referencing-guidance.pdf), 
+> [Generic name (brand name)] is recommended by the National Comprehensive Cancer Network® (NCCN®) as a treatment option for [setting and cancer type]
 
-The citation for guidelines should follow the [American Medical Association (AMA)](https://mdanderson.libanswers.com/faq/26180) style format:
-> {Source}. {Tumor type} (Version {version number}.{year}). {URL}. Accessed {month date} {day date}, {year date}.
+The citation for guidelines should follow the [NCCN's referencing guidance](https://www.nccn.org/docs/default-source/business-policy/nccn-referencing-guidance.pdf): 
+> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 202X. All rights reserved. Accessed Month and Day, Year]. To view the most recent and complete version of the guideline, go online to NCCN.org.
 
 For example,
-> National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.
+> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 2, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.
 
 [Return to Table of Contents](#table-of-contents)
 

diff --git a/molecular-oncology-almanac.json b/molecular-oncology-almanac.json
@@ -799,7 +799,7 @@
         "therapy_resistance": "",
         "favorable_prognosis": "",
         "predictive_implication": "FDA-Approved",
-        "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresctable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
+        "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
         "source_type": "FDA",
         "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15th, 2020.",
         "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf",
@@ -826,7 +826,7 @@
         "therapy_resistance": "",
         "favorable_prognosis": "",
         "predictive_implication": "FDA-Approved",
-        "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresctable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
+        "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.",
         "source_type": "FDA",
         "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15th, 2020.",
         "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf",
@@ -4447,7 +4447,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Dabrafenib",
@@ -4481,7 +4481,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Dabrafenib + Trametinib",
@@ -4515,7 +4515,7 @@
         "exon": 15,
         "rsid": "rs121913227",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Dabrafenib + Trametinib",
@@ -4651,7 +4651,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Trametinib",
@@ -4685,7 +4685,7 @@
         "exon": 15,
         "rsid": "rs121913227",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Trametinib",
@@ -4719,7 +4719,7 @@
         "exon": 15,
         "rsid": "rs121913227",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Encorafenib",
@@ -4753,7 +4753,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Encorafenib",
@@ -4821,7 +4821,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Melanoma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Melanoma",
         "oncotree_code": "MEL",
         "therapy_name": "Vemurafenib",
@@ -10941,7 +10941,7 @@
         "exon": "",
         "rsid": "",
         "disease": "Gastrointestinal Stromal Tumor",
-        "context": "Unresctable and/or metastatic",
+        "context": "Unresectable and/or metastatic",
         "oncotree_term": "Gastrointestinal Stromal Tumor",
         "oncotree_code": "GIST",
         "therapy_name": "Imatinib",
@@ -15021,7 +15021,7 @@
         "exon": 18,
         "rsid": "",
         "disease": "Gastrointestinal Stromal Tumor",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Gastrointestinal Stromal Tumor",
         "oncotree_code": "GIST",
         "therapy_name": "Avapritinib",
@@ -15055,7 +15055,7 @@
         "exon": 18,
         "rsid": "rs121908585",
         "disease": "Gastrointestinal Stromal Tumor",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Gastrointestinal Stromal Tumor",
         "oncotree_code": "GIST",
         "therapy_name": "Avapritinib",
@@ -23959,15 +23959,15 @@
         "therapy_resistance": "",
         "favorable_prognosis": "",
         "predictive_implication": "FDA-Approved",
-        "description": "Neratinib is indicated for extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy",
+        "description": "The U.S. Food and Drug Administration (FDA) approved neratinib as a single agent for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy.",
         "source_type": "FDA",
-        "citation": "Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.",
-        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf",
+        "citation": "Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf",
         "doi": "",
         "pmid": "",
         "nct": "",
-        "publication_date": "2020-05-01",
-        "last_updated": "2020-11-12"
+        "publication_date": "2017-07-17",
+        "last_updated": "2024-01-11"
     },
     {
         "feature_type": "Copy Number",
@@ -27980,7 +27980,7 @@
         "exon": 15,
         "rsid": "rs113488022",
         "disease": "Low-grade glioma",
-        "context": "Unresctable or metastatic",
+        "context": "Unresectable or metastatic",
         "oncotree_term": "Low-Grade Glioma, NOS",
         "oncotree_code": "LGGNOS",
         "therapy_name": "Dabrafenib + Trametinib",
@@ -30524,5 +30524,31 @@
         "nct": "",
         "publication_date": "2023-11-16",
         "last_updated": "2023-12-07"
+    },
+    {
+        "feature_type": "Copy Number",
+        "gene": "ERBB2",
+        "direction": "Amplification",
+        "cytoband": "",
+        "disease": "Breast Cancer",
+        "context": "Advanced or metastatic",
+        "oncotree_term": "Invasive Breast Carcinoma",
+        "oncotree_code": "BRCA",
+        "therapy_name": "Neratinib + Capecitabine",
+        "therapy_strategy": "ER signaling inhibition + Thymidylate synthase inhibitor",
+        "therapy_type": "Targeted therapy + Chemotherapy",
+        "therapy_sensitivity": 1,
+        "therapy_resistance": "",
+        "favorable_prognosis": "",
+        "predictive_implication": "FDA-Approved",
+        "description": "The U.S. Food and Drug Administration (FDA) approved neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",
+        "source_type": "FDA",
+        "citation": "Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed January 11, 2024.",
+        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf",
+        "doi": "",
+        "pmid": "",
+        "nct": "",
+        "publication_date": "2020-02-25",
+        "last_updated": "2024-01-11"
     }
 ]